Durham, NC – According to filings with the U.S. Securities and Exchange Commission, Grid Therapeutics is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Edward Patz played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Grid Therapeutics

Grid Therapeutics is an emerging clinical stage biotechnology company located in Durham, North Carolina. We have made a commitment to our patients and families to develop better and safer therapeutic antibodies for cancer. Grid has a unique and innovative platform to discover human-derived antibodies against novel tumor-specific targets, and can rapidly translate these findings into clinical practice. The Management Team was assembled to rapidly advance these assets to the clinic and have the skillsets and experience to deliver a unique portfolio in the immune-oncology space. The Board of Directors has a deep understanding of the current oncology landscape and is poised to support the Management Team deliver an efficient and impactful development plan. The Advisors and Consultants give context and insight to a wide range of topics such as clinical practice, groundbreaking laboratory techniques, manufacturing, and corporate governance.

To learn more about Grid Therapeutics, visit http://gridtherapeutics.com/

Contact:
Edward Patz, Chief Executive Officer
919-987-7190
https://www.linkedin.com/in/edward-ned-patz-04438a44/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved